Project Details
Projekt Print View

Cancer cell-specific RNA interference in vivo

Subject Area Pharmacy
Biological and Biomimetic Chemistry
Term from 2019 to 2023
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 405833972
 
Final Report Year 2023

Final Report Abstract

Technology for suppression of gene expression by small interfering RNAs (siRNAs) led to several clinically approved drugs for metabolic diseases. However, there is still no practical solution for targeting pathological cells within normal tissue by siRNAs. Many disease-associated cells produce elevated levels of reactive oxygen species (ROS), e.g., in cancer and chronic granulomatous disease (CGD), that can be used for their targeting. Though ROS-activated carriers for siRNA delivery are known, they are based on sophisticated, heavily modified polymers and lipids. We developed in this project a simpler prodrug approach based on a minor chemical modification of guide strands of siRNAs with a 5’-O-(4-boronobenzyl)-phosphorothioate group, which is stable during RNA synthesis and under physiological conditions, but is cleaved in the presence of ROS to generate active siRNAs. We demonstrated ROS-responsive activation of the prodrugs for suppression of expression of kinesin family member 11 (KIF11) in vitro as well as initiation factor of protein translation (eEF2) and N-end ruledependent ubiquitin ligases Ubr1, Ubr2, Ubr4, Ubr5 eEF2 genes in vivo.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung